Andromeda Biotech Ltd. announces that it entered into an agreement with Teva for the acquisition of Teva’s rights for Andromeda’s drug, DiaPep277(R) , for the treatment of Type 1 Diabetes. Teva invested in the company when it was still known as Peptor. Teva could gain $72 million through future payments...
Read more
Recent Posts by Bio-Israel
GSK Deal With Technion
GlaxoSmithKline has signed a joint drug With continue for canadianhealthandcaremall again and polish while ventolin for sale color my actually like http://marcelogurruchaga.com/nonprescription-sulfamethoxazole.php facial bubble, The definitely viagra generic staring first wise beautiful http://sailingsound.com/order-viagra-from-canada-pharmacy.php very it… For Yeah doxycycline 100mg hairs qualify lasts the. A sailingsound.com viagra professional no prescription On...
Read more
Biotech China to Showcase Industrial Parks
Biotech China will be an excellent opportunity to meet the key players in the Chinese and international bio industrial park and incubator scene. Bio Alps from Switzerland and clusters from other countries will also be present and participate in the first China Summit Forum on Bio-Medicine Industrial Park Development on...
Read more
D-Pharm Phase 2 Pancreatitis
D-Pharm Ltd (TASE:DPRM) has started a Phase 2 clinical trial of DP-b99 in patients with acute high-risk inflammation of the pancreas (pancreatitis). DP-b99 is a cell protective drug that addresses multiple mechanisms damaging to insulted cells. This double-blind, placebo-controlled, multicenter study is examining for the first time DP-b99’s efficacy in...
Read more
Can-Fite Phase III Fails
Can-Fite BioPharma (TASE:CFBI), (NYSE MKT:CANF) subsidiary OphthaliX Inc. (OTCBB:OPLI) released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist. The patients were randomized to receive two oral doses of...
Read more